AsymBio Launches Integrated Technology Platforms to Transform Biopharmaceutical Development
AsymBio's Innovative Approach to Biopharmaceutical Development
AsymBio, a subsidiary of Asymchem Group, has recently announced the establishment of groundbreaking integrated technology platforms that touch upon every stage of biopharmaceutical development. This initiative aims to streamline processes, from initial development through to commercial manufacturing, ensuring that clients reap the benefits of an optimized workflow.
Key Features of AsymBio's Platforms
One of the standout platforms is AmigoCHO™, which enables the development of stable, high-quality clones that yield high titers. This platform enhances the establishment, expansion, and selection processes pivotal in producing effective biopharmaceutical products.
The upstream process development platform facilitates the optimization and characterization stages necessary for progressing from preclinical material preparation to technology transfer that supports Investigational New Drug (IND) and Biologics License Application (BLA) submissions. Impressively, this platform can reduce timelines to as little as nine weeks, thereby speeding up crucial developmental phases.
The downstream process development platform advances purification processes that significantly improve product purity while reducing impurities. It encompasses chromatography and filtration development, technology transfer, scaling, and thorough characterization.
An innovative conjugation toolkit has also been introduced, designed for the rapid development and optimization of various bioconjugate modalities including Antibody-Drug Conjugates (ADCs) and others. This toolkit embraces advancements in conjugation techniques, such as cysteine/lysine conjugation and enzymatic methods, which have garnered accolades, including a nomination for Best ADC Platform Technology at the 2025 ADC World Awards.
In addition, AsymBio's IMPACT pharmaceutical development platform takes on product accountability across indications, molecules, and developmental phases. It supports formulations that are high-concentration, lyophilized, liquid, or frozen, thereby accommodating a variety of complex biological products.
Furthermore, the payload conjugation CMC development platform caters to diverse linkage and payload options such as auristatin and maytansina, underpinned by AsymBio's vast experience in CMC processes, which supports over 70 IND projects and 13 New Drug Applications (NDAs).
Last but not least, the integrated analytical platform stands out by offering robust development of analytical methods and thorough product characterization, covering essential quality attributes across the product lifecycle, which includes physicochemical platforms, mass spectrometry, and bioassay platforms.
Commitment to R&D and Global Client Success
AsymBio continues to fuel its growth through significant investments in R&D and advanced technological platforms. By merging cutting-edge scientific methods with large-scale manufacturing expertise, the company strives to help global clients navigate the complexities of biopharmaceutical development, enhance manufacturing efficiencies, ensure product quality, and drive reliable commercialization of innovative therapies.
About AsymBio
Focused solely on biopharmaceutical CDMO services, AsymBio provides a comprehensive range of offerings from initial development through clinical, toxicology, and commercial-scale manufacturing. With a strong foothold in ADCs, the company is expanding its capabilities further, ensuring a holistic approach to therapies involving antibodies and recombinant proteins.
For more details about their innovative solutions and offerings, visit www.asymbio.com or follow them on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.